Millert-Kalińska Sonja, Przybylski Marcin, Pruski Dominik, Stawicka-Niełacna Małgorzata, Mądry Radosław
Doctoral School, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
Department of Obstetrics and Gynecology, District Public Hospital in Poznan, 60-479 Poznań, Poland.
Healthcare (Basel). 2023 Jul 17;11(14):2043. doi: 10.3390/healthcare11142043.
Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the Poznań University of Medical Sciences (SKPP). The relationships among starting treatment in our centre, the type of first intervention, and the final decision were significant ( < 0.001). Patients in the SKPP group were more likely to primarily have a laparoscopy and less likely to have an exploratory laparotomy. Neoadjuvant chemotherapy (NACT) after a laparotomy was less often a final decision among SKPP patients (9% vs. 22%), in contrary to NACT after a laparoscopy (23% vs. 4%). Factors affecting the shortening of progression-free survival (PFS) were an advanced stage of the disease, a histopathological diagnosis, the type of cytoreduction, and the final decision. Significance according to the final decision was revealed for PDS vs. NACT after a laparotomy ( < 0.001) and for PDS vs. NACT after a laparoscopy ( = 0.011). Our study supports the benefits of treating ovarian cancer in an oncology centre with a high patient throughput. Further observations might also answer the question about overall survival (OS).
卵巢癌(OC)是全球第八大常见癌症,通常在晚期被诊断出来。尽管有许多可用数据,但波兰尚未对治疗结果进行综述。本研究纳入了2018年至2021年间在波兹南医科大学肿瘤学系(SKPP)接受治疗的289例初治患者。在我们中心开始治疗、首次干预类型和最终决策之间的关系具有显著性(<0.001)。SKPP组的患者更有可能首先进行腹腔镜检查,而进行 exploratory laparotomy(此处可能有误,推测为“剖腹探查术”)的可能性较小。剖腹手术后的新辅助化疗(NACT)在SKPP患者中较少作为最终决策(9%对22%),这与腹腔镜检查后的NACT情况相反(23%对4%)。影响无进展生存期(PFS)缩短的因素包括疾病晚期、组织病理学诊断、细胞减灭术类型和最终决策。剖腹手术后PDS与NACT相比(<0.001)以及腹腔镜检查后PDS与NACT相比(=0.011),根据最终决策显示出显著性。我们的研究支持在患者吞吐量高的肿瘤中心治疗卵巢癌的益处。进一步的观察也可能回答关于总生存期(OS)的问题。